Gastrointestinal Cancers: mCRC (Issue 9)

Nintedanib may be a promising treatment option for patients with metastatic colorectal cancer who are not responding to treatment.

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses how depth of response plays an important role in the treatment of colorectal cancer.

Axel Grothey, MD, Mayo Clinic in Rochester, Minnesota, discusses the Lume 1 and 2 trials as well as new treatment options for metastatic colorectal cancer.

Kanwal Raghav,MBBS, MD, Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, the University of Texas M.D. Anderson Cancer Center, discusses HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer.

A recent retrospective analysis of the phase III 80405 trial determined that tumor location played a significant role in survival outcome differences for patients with KRAS wild-type metastatic colorectal cancer (mCRC).

Circulating tumor DNA (ctDNA) detection has 48% sensitivity and 100% specificity in the prediction of radiologic recurrence at 36 months in postoperative patients with stage II colon cancer.

Two recent clinical trials have demonstrated intriguing findings for new combination regimens for patients with microsatellite stable or instable metastatic colorectal cancer.

Adding selective internal radiation therapy with SIR-Spheres Y-90 resin microspheres to standard first-line chemotherapy significantly increased hepatic depth of response in patients with metastatic colorectal cancer.